Literature DB >> 20926374

Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells.

Jacinta Serpa1, Francisco Caiado, Tânia Carvalho, Cheila Torre, Luís G Gonçalves, Cristina Casalou, Pedro Lamosa, Margarida Rodrigues, Zhenping Zhu, Eric W F Lam, Sérgio Dias.   

Abstract

The short chain fatty acid (SCFA) butyrate is a product of colonic fermentation of dietary fibers. It is the main source of energy for normal colonocytes, but cannot be metabolized by most tumor cells. Butyrate also functions as a histone deacetylase (HDAC) inhibitor to control cell proliferation and apoptosis. In consequence, butyrate and its derived drugs are used in cancer therapy. Here we show that aggressive tumor cells that retain the capacity of metabolizing butyrate are positively selected in their microenvironment. In the mouse xenograft model, butyrate-preselected human colon cancer cells gave rise to subcutaneous tumors that grew faster and were more angiogenic than those derived from untreated cells. Similarly, butyrate-preselected cells demonstrated a significant increase in rates of homing to the lung after intravenous injection. Our data showed that butyrate regulates the expression of VEGF and its receptor KDR at the transcriptional level potentially through FoxM1, resulting in the generation of a functional VEGF:KDR autocrine growth loop. Cells selected by chronic exposure to butyrate express higher levels of MMP2, MMP9, α2 and α3 integrins, and lower levels of E-cadherin, a marker for epithelial to mesenchymal transition. The orthotopic model of colon cancer showed that cells preselected by butyrate are able to colonize the animals locally and at distant organs, whereas control cells can only generate a local tumor in the cecum. Together our data shows that a butyrate-rich microenvironment may select for tumor cells that are able to metabolize butyrate, which are also phenotypically more aggressive.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926374      PMCID: PMC2998102          DOI: 10.1074/jbc.M110.156026

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.

Authors:  S Dias; K Hattori; B Heissig; Z Zhu; Y Wu; L Witte; D J Hicklin; M Tateno; P Bohlen; M A Moore; S Rafii
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation.

Authors:  Brian F Hinnebusch; Shufen Meng; James T Wu; Sonia Y Archer; Richard A Hodin
Journal:  J Nutr       Date:  2002-05       Impact factor: 4.798

3.  Insulin-like growth factor-II renders LIM 2405 human colon cancer cells resistant to butyrate-induced apoptosis: a potential mechanism for colon cancer cell survival in vivo.

Authors:  S L Leng; K S Leeding; P R Gibson; L A Bach
Journal:  Carcinogenesis       Date:  2001-10       Impact factor: 4.944

4.  Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.

Authors:  F Chai; A Evdokiou; G P Young; P D Zalewski
Journal:  Carcinogenesis       Date:  2000-01       Impact factor: 4.944

5.  Utilization of nutrients by isolated epithelial cells of the rat colon.

Authors:  W E Roediger
Journal:  Gastroenterology       Date:  1982-08       Impact factor: 22.682

6.  Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways.

Authors:  Susana Constantino Rosa Santos; Sérgio Dias
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

7.  The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.

Authors:  Hector R Contreras; Rodrigo A Ledezma; Jorge Vergara; Federico Cifuentes; Cristina Barra; Pablo Cabello; Ivan Gallegos; Bernardo Morales; Christian Huidobro; Enrique A Castellón
Journal:  Urol Oncol       Date:  2009-05-17       Impact factor: 3.498

8.  Acquisition of resistance to butyrate enhances survival after stress and induces malignancy of human colon carcinoma cells.

Authors:  Isabel López de Silanes; Nieves Olmo; Javier Turnay; Gonzalo González de Buitrago; Pablo Pérez-Ramos; Ana Guzmán-Aránguez; Marta García-Díez; Emilio Lecona; Myriam Gorospe; M Antonia Lizarbe
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

Review 9.  Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals.

Authors:  M Bugaut
Journal:  Comp Biochem Physiol B       Date:  1987

10.  Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice.

Authors:  Tatsuo Furuyama; Kazuko Kitayama; Yuri Shimoda; Minetaro Ogawa; Kiyoaki Sone; Kiyomi Yoshida-Araki; Hiroshi Hisatsune; Shin-ichi Nishikawa; Keiko Nakayama; Keiichi Nakayama; Kyoji Ikeda; Noboru Motoyama; Nozomu Mori
Journal:  J Biol Chem       Date:  2004-06-07       Impact factor: 5.157

View more
  26 in total

1.  Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells.

Authors:  Filipa Lopes-Coelho; Carolina Nunes; Sofia Gouveia-Fernandes; Rita Rosas; Fernanda Silva; Paula Gameiro; Tânia Carvalho; Maria Gomes da Silva; José Cabeçadas; Sérgio Dias; Luís G Gonçalves; Jacinta Serpa
Journal:  Oncotarget       Date:  2017-08-16

Review 2.  Neuropilins: expression and roles in the epithelium.

Authors:  Jonathan R L Wild; Carolyn A Staton; Keith Chapple; Bernard M Corfe
Journal:  Int J Exp Pathol       Date:  2012-04       Impact factor: 1.925

3.  Lactobacillus plantarum-derived metabolites sensitize the tumor-suppressive effects of butyrate by regulating the functional expression of SMCT1 in 5-FU-resistant colorectal cancer cells.

Authors:  Hye-Ju Kim; JaeJin An; Eun-Mi Ha
Journal:  J Microbiol       Date:  2021-12-29       Impact factor: 3.422

4.  Interrelations between Gut Microbiota Composition, Nutrient Intake and Diabetes Status in an Adult Japanese Population.

Authors:  Ayumi Tamura; Masaya Murabayashi; Yuki Nishiya; Satoru Mizushiri; Kiho Hamaura; Ryoma Ito; Shoma Ono; Akihide Terada; Hiroshi Murakami; Jutaro Tanabe; Miyuki Yanagimachi; Itoyo Tokuda; Kaori Sawada; Kazushige Ihara; Makoto Daimon
Journal:  J Clin Med       Date:  2022-06-05       Impact factor: 4.964

5.  Upregulation of annexin A1 expression by butyrate in human melanoma cells induces invasion by inhibiting E-cadherin expression.

Authors:  Jimin Shin; In-Sung Song; Jhang Ho Pak; Sung-Wuk Jang
Journal:  Tumour Biol       Date:  2016-09-10

6.  STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment.

Authors:  Lidia Santos Silva; Luis Gafeira Goncalves; Fernanda Silva; Germana Domingues; Valdemar Maximo; Joana Ferreira; Eric W-F Lam; Sergio Dias; Ana Felix; Jacinta Serpa
Journal:  Tumour Biol       Date:  2015-11-12

7.  Epigenetic control of HNF-4α in colon carcinoma cells affects MUC4 expression and malignancy.

Authors:  Anna Algamas-Dimantov; Einav Yehuda-Shnaidman; Irena Peri; Betty Schwartz
Journal:  Cell Oncol (Dordr)       Date:  2013-01-11       Impact factor: 6.730

8.  Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma.

Authors:  Saurabh Singhal; Harit Kapoor; Saravanan Subramanian; Devendra K Agrawal; Sumeet K Mittal
Journal:  J Gastrointest Cancer       Date:  2019-12

9.  Butyrate histone deacetylase inhibitors.

Authors:  Kosta Steliou; Michael S Boosalis; Susan P Perrine; José Sangerman; Douglas V Faller
Journal:  Biores Open Access       Date:  2012-08

10.  Butyrylated starch affects colorectal cancer markers beneficially and dose-dependently in genotoxin-treated rats.

Authors:  Shusuke Toden; Trevor J Lockett; David L Topping; Benjamin L Scherer; Emma-Jane L Watson; Jessica G Southwood; Julie M Clarke
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.